SEARCH

SEARCH BY CITATION

References

  • 1
    Ho RH, Kim RB. Transporters and drug therapy: Implications for drug disposition and disease. Clin Pharmacol Ther2005;78:260277.
  • 2
    Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics2007;8:787802.
  • 3
    Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol2009;158:693705.
  • 4
    Szakács G, Váradi A, Özvegy-Laczka C, Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism,excretion and toxicity (ADME-Tox). Drug Discov Today2008;13:379393.
  • 5
    Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. The Role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv2004;1:2742.
  • 6
    Mukhtar RYA, Reid J, Reckless JPD. Pitavastatin. Int J Clin Prac2005;59:239252.
  • 7
    Kojima J, Ohshima T, Yoneda M, Sawada H. Effect of biliary excretion on the pharmacokinetics of pitavastatin (NK-104) in dogs. Drug Metab Pharmacokinet2001;16:497502.
  • 8
    Kimata H, Fujino H, Koide T, Yamada Y, Tsunenari Y, Yanagawa Y. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats. Drug Metab Pharmacokinet1998;13:484498.
  • 9
    Ho RH, Tirona RG, Leake BF, et al.Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics. Gastroenterology2006;130:17931806.
  • 10
    Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther2003;25:28222835.
  • 11
    McTaggart F, Buckett L, Davidson R, et al.Preclinical and clinical pharmacology of rosuvastain, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol2001;87(suppl 5A):B28B32.
  • 12
    Chiara B, Andrea P, Andrea C, Catapano AL, Paoletti R. Novel Statins: Pharmacological and clinical results. Cardiovasc Drugs Ther2002;16:251257.
  • 13
    Ieiri I, Suwannakul S, Maeda K, et al.SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) variant alleles and pharmacokinetics of Pitavastatin in healthy volunteers. Clin Pharmacol Ther2007;82:541547.
  • 14
    Nezask K, Higaki K, Takeuchi M, Nakano M, Koike M. Uptake of rosuvastatin by isolated rat hepatocytes: Comparison with pravastatin. Xenobiotica2003;33:379388.
  • 15
    Huang LY, Wang Y, Grimm S. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistant protein. Drug Metab Dispos2006;34:738742.
  • 16
    Nishizato Y, Ieiri I, Suzuki H, et al.Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther2003;73:554565.
  • 17
    Mwinyi J, Köpke K, Schaefer M, Roots I, Gerloff T. Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur J Clin Pharmacol2008;64:257266.
  • 18
    Tirona RG, Leake BF, Merino G, Kim RB. Polymorphismsin OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Inorg Chem2001;276:3566935675.
  • 19
    Tamura A, Onishi Y, An R, Nakagawa H, Kamachi T, Okura I, Ishikawa T. In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. Drug Metab Pharmacokinet2007;22:428440.
  • 20
    Tamura A, Watanabe M, Saito H, Nakagawa H, Kamachi T, Okura I, Ishikawa T. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: Identification of alleles that are defective in porphyrin transport. Mol Pharmacol2006;70:287296.
  • 21
    Kuniaki M, Robert WR, Csilla OL, et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol2005;56:161172.
  • 22
    Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A. Mechanisms of resistance to anticancer drugs: The role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics2005;6:115138.
  • 23
    Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, Bates SE. ABCG2: A perspective. Adv Drug Delivery Rev2009;61:313.
  • 24
    Williams, Feely. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet2002;41:343370.
  • 25
    Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: Are all statins the same?Drug Saf2002;25:649663.
  • 26
    Abe T, Kakyo M, Tokui T, et al.Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem1999;274:1715917163.
  • 27
    Jessica M, Karla K, Melanie S, Roots I, Gerloff T. Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur J Clin Pharmacol2008;64:257266.
  • 28
    Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics2008;9:1933.
  • 29
    Ho WF, Koo SH, Yee JY, Lee EJ. Genetic variations of the SLCO1B1 gene in the Chinese, Malay and Indian populations of Singapore. Drug Metab Pharmacokinet2008;23:476482.
  • 30
    Jada SR, Xiaochen S, Yan LY, et al.Pharmacogenetics of SLCO1B1: Haplotypes, htSNPs and hepatic expression in three distinct Asian populations. Eur J Clin Pharmacol2007;63:555563.
  • 31
    Xiang X, Jada SR, Li HH, et al.Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genomics2006;16:683691.
  • 32
    Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants,SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 + C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics2005;15:513521.
  • 33
    Chung JY, Cho JY, Yu KS, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther2005;78:342350.
  • 34
    Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther2005;78:330341.
  • 35
    Choi JH, Lee MG, Cho JY, Lee JE, Kim KH, Park K. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin Pharmacol Ther2007;83:251257.
  • 36
    Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther2007;82:726733.
  • 37
    Shinji M, Naohiko A, Hidehito K. Single nucleotide polymorphisms result in impaired membrane lacalization and reduced ATPase activity in multidrug transporter ABCG2. Int J Cancer2004;109:238246.
  • 38
    Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, Bates SE. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol2005;56:161172.
  • 39
    Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, Schuetz EG. Natural allelic variants of breastcancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics2003;13;1928.
  • 40
    Itoda M, Saito Y, Shirao K, et al. Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotecan. Drug Metab Pharmacokinet2003;18:212217.
  • 41
    Zhang W, Yu BN, He YJ, et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Int J Clin Chem Diagn Lab Med2006;373:99103.
  • 42
    Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol2005;68:800807.
  • 43
    Richard HHM, Richard BKM. Transporters and drug therapy: Implications for drug disposition and disease. Clin Pharmacol Ther2005;78:260277.
  • 44
    Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol2005;1:429445.
  • 45
    Kivistö KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res2007;24:239247.
  • 46
    Fan L, Zhang W, Guo D, et al.The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther2008;83:471476.
  • 47
    Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, Sawada Y. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos2006;34:577582.
  • 48
    Suwannakul S, Ieiri I, Kimura M, et al.Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. J Human Genet2008;53:899904.
  • 49
    Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: Implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol2009;5:703729.
  • 50
    Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos2006;34:12291236.
  • 51
    Hasunuma T, Nakamura M, Yachi T, Arisawa N, Fukushima K, Iijima H, Saito Y. The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. J Clin Ther Med2003;19:381389.
  • 52
    Mathew P, Cuddy T, Tracewell WG, Tracewell WG, Salazar D.An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers. Clin Pharmacol Ther2004;75:3341.
  • 53
    Zhang W, Deng S, Chen XP, et al.Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Pharmacol Ther2008;30:12831289.
  • 54
    Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther2004;75:455463.
  • 55
    Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol2003;59:5156.
  • 56
    Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther2003;73:322329.
  • 57
    Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol2002;58:527531.
  • 58
    Naomi M, Yuichi S. Drug Transporters: Their role and importance in the selection and development of new drugs. Drug metab2002;17:93108.